TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Melissa L Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.